Literature DB >> 2901835

Expression of a P-glycoprotein gene is inducible in a multidrug-resistant human leukemia cell line.

V Gekeler1, G Frese, H Diddens, H Probst.   

Abstract

A human T lymphoblastoid CCRF-CEM cell line exhibiting cross resistance to a variety of drugs was selected with increasing doses of actinomycin D. A subline, designated CCRF ACTD400+, was permanently cultured in the presence of 400 ng/ml Actinomycin D for several months. Using a fragment of the human mdr1 cDNA we found high expression of a 5 kb mRNA species which was not detectable in the sensitive parental CCRF-CEM cell line. The extent of the mdr-mRNA expression in resistant cells, however, depended on the presence or absence of actinomycin D in the culture medium: when the inhibitor was omitted, the expression decreased to about 60% after one month. In reverse, the steady state level of the P-glycoprotein mRNA increased about 2.5-fold within 72 h after the original dose of the drug was added again. In further experiments we recorded the actinomycin D or adriamycin dose response curves of the variously treated sublines by evaluation of [3H]uridine or [3H]thymidine incorporation, respectively, into acid insoluble material. Consistently, the drug sensitivity of the respective macromolecular synthesis was found to decrease with increasing mdr-mRNA levels.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2901835     DOI: 10.1016/s0006-291x(88)80559-x

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Influence of sequential exposure to R-verapamil or B8509-035 on rhodamine 123 accumulation in human lymphoblastoid cell lines.

Authors:  E Roller; B Klumpp; J Krause; M Eichelbaum; K Schumacher
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

2.  Effects of verapamil enantiomers and major metabolites on the cytotoxicity of vincristine and daunomycin in human lymphoma cell lines.

Authors:  K Häussermann; B Benz; V Gekeler; K Schumacher; M Eichelbaum
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Drug-induced changes in the expression of MDR-associated genes: investigations on cultured cell lines and chemotherapeutically treated leukemias.

Authors:  V Gekeler; J Beck; A Noller; A Wilisch; G Frese; M Neumann; R Handgretinger; G Ehninger; H Probst; D Niethammer
Journal:  Ann Hematol       Date:  1994       Impact factor: 3.673

Review 4.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

Review 5.  Transcriptional regulation of multidrug resistance in breast cancer.

Authors:  R I Glazer; C Rohlff
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

6.  Transcriptional regulation of MDR genes.

Authors:  K W Scotto; D A Egan
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

7.  Multiple gene expression analysis reveals distinct differences between G2 and G3 stage breast cancers, and correlations of PKC eta with MDR1, MRP and LRP gene expression.

Authors:  J Beck; B Bohnet; D Brügger; P Bader; J Dietl; R J Scheper; R Kandolf; C Liu; D Niethammer; V Gekeler
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

8.  P-glycoprotein expression in Ehrlich ascites tumour cells after in vitro and in vivo selection with daunorubicin.

Authors:  D Nielsen; J Eriksen; C Maare; A H Jakobsen; T Skovsgaard
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

9.  Mdr1/P-glycoprotein, topoisomerase, and glutathione-S-transferase pi gene expression in primary and relapsed state adult and childhood leukaemias.

Authors:  V Gekeler; G Frese; A Noller; R Handgretinger; A Wilisch; H Schmidt; C P Muller; R Dopfer; T Klingebiel; H Diddens
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640

10.  Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance.

Authors:  V Gekeler; R Boer; F Uberall; W Ise; C Schubert; I Utz; J Hofmann; K H Sanders; C Schächtele; K Klemm; H Grunicke
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.